Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in adults over 70 years old

2.

Shallis

RM

,

Wang

R

,

Davidoff

A

,

Ma

X

,

Zeidan

AM

.

Epidemiology of acute myeloid leukemia: recent progress and enduring challenges

.

Blood Rev

.

2019

;

36

:

70

-

87

.

3.

National Cancer Institute

.

SEER Cancer Stat Facts: Acute Myeloid Leukemia

. Accessed 5 March 2024. https://seer.cancer.gov/statfacts/html/amyl.html.

4.

Extermann

M

,

Artz

A

,

Rebollo

MA

, et al.

Treating acute myelogenous leukemia in patients aged 70 and above: recommendations from the International Society of Geriatric Oncology (SIOG)

.

J Geriatr Oncol

.

2024

;

15

(

2

):

101626

.

5.

Oran

B

,

Weisdorf

DJ

.

Survival for older patients with acute myeloid leukemia: a population-based study

.

Haematologica

.

2012

;

97

(

12

):

1916

-

1924

.

6.

Colovic

M

,

Colovic

N

,

Radojkovic

M

, et al.

Induction chemotherapy versus palliative treatment for acute myeloid leukemia in a consecutive cohort of elderly patients

.

Ann Hematol

.

2012

;

91

(

9

):

1363

-

1370

.

7.

Medeiros

BC

,

Satram-Hoang

S

,

Hurst

D

,

Hoang

KQ

,

Momin

F

,

Reyes

C

.

Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States

.

Ann Hematol

.

2015

;

94

(

7

):

1127

-

1138

.

8.

Bhatt

VR

,

Shostrom

V

,

Gundabolu

K

,

Armitage

JO

.

Utilization of initial chemotherapy for newly diagnosed acute myeloid leukemia in the United States

.

Blood Adv

.

2018

;

2

(

11

):

1277

-

1282

.

9.

Zeidan

AM

,

Podoltsev

NA

,

Wang

X

, et al.

Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: a population-level analysis

.

Cancer

.

2019

;

125

(

23

):

4241

-

4251

.

10.

Talati

C

,

Dhulipala

VC

,

Extermann

MT

, et al.

Comparisons of commonly used front-line regimens on survival outcomes in patients aged 70 years and older with acute myeloid leukemia

.

Haematologica

.

2020

;

105

(

2

):

398

-

406

.

11.

Brunner

AM

,

Huggar

D

,

Copher

R

, et al.

Economic burden during remission and after relapse among older patients with newly diagnosed acute myeloid leukemia without hematopoietic stem cell transplant: a retrospective study using the SEER-Medicare database

.

Leuk Res

.

2023

;

132

:

107353

.

12.

Dharmani

C

,

Wang

E

,

Tu

N

,

Salas

M

,

Kamel

YM

.

Characteristics and outcomes of elderly patients with acute myeloid leukemia who receive no treatment in the Surveillance, Epidemiology and End Results-Medicare database

.

Future Oncol

.

2023

;

19

(

2

):

159

-

171

.

13.

Linet

MS

,

Curtis

RE

,

Schonfeld

SJ

,

Vo

JB

,

Morton

LM

,

Dores

GM

.

Survival of adult AML patients treated with chemotherapy in the U.S. population by age, race and ethnicity, sex, calendar-year period, and AML subgroup, 2001-2019

.

EClinicalMedicine

.

2024

;

71

:

102549

.

14.

Döhner

H

,

Wei

AH

,

Löwenberg

B

.

Towards precision medicine for AML

.

Nat Rev Clin Oncol

.

2021

;

18

(

9

):

577

-

590

.

15.

Döhner

H

,

Wei

AH

,

Appelbaum

FR

, et al.

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

.

Blood

.

2022

;

140

(

12

):

1345

-

1377

.

16.

Bazinet

A

,

Kantarjian

HM

.

Moving toward individualized target-based therapies in acute myeloid leukemia

.

Ann Oncol

.

2023

;

34

(

2

):

141

-

151

.

17.

Shimony

S

,

Stahl

M

,

Stone

RM

.

Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management

.

Am J Hematol

.

2023

;

98

(

3

):

502

-

526

.

18.

Ringdén

O

,

Boumendil

A

,

Labopin

M

, et al.

Outcome of allogeneic hematopoietic stem cell transplantation in patients age >69 years with acute myelogenous leukemia: on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

.

Biol Blood Marrow Transplant

.

2019

;

25

(

10

):

1975

-

1983

.

19.

Lin

RJ

,

Artz

AS

.

Allogeneic hematopoietic cell transplantation for older patients

.

Hematology Am Soc Hematol Educ Program

.

2021

;

2021

(

1

):

254

-

263

.

20.

Maakaron

JE

,

Zhang

MJ

,

Chen

K

, et al.

Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis

.

Bone Marrow Transplant

.

2022

;

57

(

6

):

911

-

917

.

21.

Maffini

E

,

Ngoya

M

,

Galimard

JE

, et al.

Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

.

Bone Marrow Transplant

.

2023

;

58

(

9

):

1033

-

1041

.

22.

Weller

JF

,

Lengerke

C

,

Finke

J

, et al.

Allogeneic hematopoietic stem cell transplantation in patients aged 60-79 years in Germany (1998-2018): a registry study

.

Haematologica

.

2024

;

109

(

2

):

431

-

443

.

23.

Sasaki

K

,

Ravandi

F

,

Kadia

TM

, et al.

De novo acute myeloid leukemia: a population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017

.

Cancer

.

2021

;

127

(

12

):

2049

-

2061

.

24.

Bazarbachi

A

,

Labopin

M

,

Moukalled

N

, et al.

Improvements in posttransplant outcomes over two decades in older patients with acute myeloid leukemia in the EBMT ALWP study

.

Clin Cancer Res

.

2024

;

30

(

9

):

1778

-

1787

.

25.

U.S. Social Security Administration: Actuarial Life Table. Social Security Administration; 2021

. Accessed 23 May 2024. https://www.ssa.gov/oact/STATS/table4c6.html.

26.

Muffly

L

,

Pasquini

MC

,

Martens

M

, et al.

Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States

.

Blood

.

2017

;

130

(

9

):

1156

-

1164

.

27.

Bhatt

VR

,

Chen

B

,

Gyawali

B

,

Lee

SJ

.

Socioeconomic and health system factors associated with lower utilization of hematopoietic cell transplantation in older patients with acute myeloid leukemia

.

Bone Marrow Transplant

.

2018

;

53

(

10

):

1288

-

1294

.

28.

Flannelly

C

,

Tan

BE

,

Tan

JL

, et al.

Barriers to hematopoietic cell transplantation for adults in the United States: a systematic review with a focus on age

.

Biol Blood Marrow Transplant

.

2020

;

26

(

12

):

2335

-

2345

.

29.

Mishra

A

,

Preussler

JM

,

Bhatt

VR

, et al.

Breaking the age barrier: physicians' perceptions of candidacy for allogeneic hematopoietic cell transplantation in older adults

.

Transplant Cell Ther

.

2021

;

27

(

7

):

617.e1

-

617.e7

.

30.

Versluis

J

,

Hazenberg

CL

,

Passweg

JR

, et al.

Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis

.

Lancet Haematol

.

2015

;

2

(

10

):

e427

-

e436

.

31.

Ustun

C

,

Le-Rademacher

J

,

Wang

HL

, et al.

Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study

.

Leukemia

.

2019

;

33

(

11

):

2599

-

2609

.

32.

Sorror

ML

,

Gooley

TA

,

Storer

BE

, et al.

An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML

.

Blood

.

2023

;

141

(

3

):

295

-

308

.

https://doi.org/10.3324/haematol.2024.285879

33.

Niederwieser

D

,

Hasenclever

D

,

Berdel

WE

, et al.

Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III study

.

Haematologica

.

Published online 8 August 2024

.

34.

Maffini

E

,

Labopin

M

,

Kröger

N

, et al.

Allogeneic hematopoietic cell transplantation for older patients with AML with active disease. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

.

Bone Marrow Transplant

.

2024

;

59

(

7

):

983

-

990

.

35.

Kurosawa

S

,

Yamaguchi

T

,

Miyawaki

S

, et al.

A Markov decision analysis of allogeneic hematopoietic cell transplantation versus chemotherapy in patients with acute myeloid leukemia in first remission

.

Blood

.

2011

;

117

(

7

):

2113

-

2120

.

36.

Cornelissen

JJ

,

Breems

D

,

van Putten

WLJ

, et al.

Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories

.

J Clin Oncol

.

2012

;

30

(

17

):

2140

-

2146

.

37.

Versluis

J

,

Kalin

B

,

Zeijlemaker

W

, et al.

Graft-versus-leukemia effect of allogeneic stem-cell transplantation and minimal residual disease in patients with acute myeloid leukemia in first complete remission

.

JCO Precis Oncol

.

2017

;

1

:

1

-

13

.

38.

Cornelissen

JJ

,

Gratwohl

A

,

Schlenk

RF

, et al.

The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach

.

Nat Rev Clin Oncol

.

2012

;

9

(

10

):

579

-

590

.

39.

Lindsley

RC

,

Mar

BG

,

Mazzola

E

, et al.

Acute myeloid leukemia ontogeny is defined by distinct somatic mutations

.

Blood

.

2015

;

125

(

9

):

1367

-

1376

.

40.

Walter

RB

,

Othus

M

,

Paietta

EM

, et al.

Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia

.

Leukemia

.

2015

;

29

(

10

):

2104

-

2107

.

41.

Papaemmanuil

E

,

Gerstung

M

,

Bullinger

L

, et al.

Genomic classification and prognosis in acute myeloid leukemia

.

N Engl J Med

.

2016

;

374

(

23

):

2209

-

2221

.

42.

Othus

M

,

Wood

BL

,

Stirewalt

DL

, et al.

Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia

.

Leukemia

.

2016

;

30

(

10

):

2080

-

2083

.

43.

Jongen-Lavrencic

M

,

Grob

T

,

Hanekamp

D

, et al.

Molecular minimal residual disease in acute myeloid leukemia

.

N Engl J Med

.

2018

;

378

(

13

):

1189

-

1199

.

44.

Heuser

M

,

Freeman

SD

,

Ossenkoppele

GJ

, et al.

2021 update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

.

Blood

.

2021

;

138

(

26

):

2753

-

2767

.

45.

Pratz

KW

,

Jonas

BA

,

Pullarkat

V

, et al.

Measurable residual disease response and prognosis in treatment-naive acute myeloid leukemia with venetoclax and azacitidine

.

J Clin Oncol

.

2022

;

40

(

8

):

855

-

865

.

46.

Bataller

A

,

Bazinet

A

,

DiNardo

CD

, et al.

Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax

.

Blood Adv

.

2024

;

8

(

4

):

927

-

935

.

47.

Cornelissen

JJ

,

Versluis

J

,

Passweg

JR

, et al.

Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years

.

Leukemia

.

2015

;

29

(

5

):

1041

-

1050

.

48.

Shouval

R

,

Fein

JA

.

The sum of the parts: what we can and cannot learn from comorbidity scores in allogeneic transplantation

.

Hematology Am Soc Hematol Educ Program

.

2023

;

2023

(

1

):

715

-

722

.

49.

Sorror

ML

,

Sandmaier

BM

,

Storer

BE

, et al.

Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies

.

JAMA

.

2011

;

306

(

17

):

1874

-

1883

.

50.

Nikolousis

E

,

Nagra

S

,

Pearce

R

, et al.

Impact of pre-transplant co-morbidities on outcome after alemtuzumab-based reduced intensity conditioning allo-SCT in elderly patients: a British Society of Blood and Marrow Transplantation study

.

Bone Marrow Transplant

.

2015

;

50

(

1

):

82

-

86

.

51.

Castagna

L

,

Fürst

S

,

Marchetti

N

, et al.

Retrospective analysis of common scoring systems and outcome in patients older than 60 years treated with reduced-intensity conditioning regimen and alloSCT

.

Bone Marrow Transplant

.

2011

;

46

(

7

):

1000

-

1005

.

52.

Polverelli

N

,

Tura

P

,

Battipaglia

G

, et al.

Multidimensional geriatric assessment for elderly hematological patients (>/=60 years) submitted to allogeneic stem cell transplantation. A French-Italian 10-year experience on 228 patients

.

Bone Marrow Transplant

.

2020

;

55

(

12

):

2224

-

2233

.

53.

Backhaus

D

,

Brauer

D

,

Pointner

R

, et al.

A high hematopoietic cell transplantation comorbidity Index (HCT-CI) does not impair outcomes after non-myeloablative allogeneic stem cell transplantation in acute myeloid leukemia patients 60 years or older

.

Bone Marrow Transplant

.

2023

;

58

(

1

):

30

-

38

.

54.

Parimon

T

,

Au

DH

,

Martin

PJ

,

Chien

JW

.

A risk score for mortality after allogeneic hematopoietic cell transplantation

.

Ann Intern Med

.

2006

;

144

(

6

):

407

-

414

.

55.

Shouval

R

,

Fein

JA

,

Shouval

A

, et al.

External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation

.

Blood Adv

.

2019

;

3

(

12

):

1881

-

1890

.

56.

Al-Shaibani

E

,

Cyriac

S

,

Chen

S

, et al.

Comparison of the prognostic ability of the HCT-CI, the modified EBMT, and the EBMT-ADT pre-transplant risk scores for acute leukemia

.

Clin Lymphoma Myeloma Leuk

.

2021

;

21

(

6

):

e559

-

e568

.

57.

Shouval

R

,

Fein

JA

,

Cho

C

, et al.

The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT

.

Blood Adv

.

2022

;

6

(

5

):

1525

-

1535

.

58.

Zarling

LC

,

Othus

M

,

Sandmaier

BM

, et al.

Utility of the treatment-related mortality (TRM) score to predict outcomes of adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation

.

Leukemia

.

2022

;

36

(

6

):

1563

-

1574

.

59.

Spyridonidis

A

,

Labopin

M

,

Gedde-Dahl

T

, et al.

Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation

.

Bone Marrow Transplant

.

2024

;

59

(

2

):

217

-

223

.

60.

Mussetti

A

,

Rius-Sansalvador

B

,

Moreno

V

, et al.

Artificial intelligence methods to estimate overall mortality and non-relapse mortality following allogeneic HCT in the modern era: an EBMT-TCWP study

.

Bone Marrow Transplant

.

2024

;

59

(

2

):

232

-

238

.

61.

Weise

G

,

Massoud

R

,

Krause

R

, et al.

Development and validation of a concise objectifiable risk evaluation score for non-relapse mortality after allogeneic hematopoietic stem cell transplantation

.

Cancers

.

2024

;

16

(

3

):

515

.

62.

Muffly

LS

,

Kocherginsky

M

,

Stock

W

, et al.

Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients

.

Haematologica

.

2014

;

99

(

8

):

1373

-

1379

.

63.

Deschler

B

,

Ihorst

G

,

Schnitzler

S

,

Bertz

H

,

Finke

J

.

Geriatric assessment and quality of life in older patients considered for allogeneic hematopoietic cell transplantation: a prospective risk factor and serial assessment analysis

.

Bone Marrow Transplant

.

2018

;

53

(

5

):

565

-

575

.

64.

Pamukcuoglu

M

,

Bhatia

S

,

Weisdorf

DJ

, et al.

Hematopoietic cell transplant-related toxicities and mortality in frail recipients

.

Biol Blood Marrow Transplant

.

2019

;

25

(

12

):

2454

-

2460

.

65.

Derman

BA

,

Kordas

K

,

Ridgeway

J

, et al.

Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults

.

Blood Adv

.

2019

;

3

(

22

):

3488

-

3498

.

66.

Olin

RL

,

Fretham

C

,

Pasquini

MC

, et al.

Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes

.

Blood Adv

.

2020

;

4

(

12

):

2810

-

2820

.

67.

Huang

LW

,

Sheng

Y

,

Andreadis

C

, et al.

Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplantation recipients

.

Biol Blood Marrow Transplant

.

2020

;

26

(

1

):

189

-

196

.

68.

Woods

JD

,

Klepin

HD

.

Geriatric assessment in acute myeloid leukemia (AML)

.

Acta Haematol

.

2024

;

147

(

2

):

219

-

228

.

69.

Bhatt

VR

,

Uy

GL

,

Klepin

HD

.

Determining treatment tolerance and fitness for intensive chemotherapy in older adults with AML: a call to action

.

Blood

.

2024

;

143

(

6

):

483

-

487

.

70.

Sung

AD

,

Koll

T

,

Gier

SH

, et al.

Preconditioning frailty phenotype influences survival and relapse for older allogeneic transplantation recipients

.

Transplant Cell Ther

.

2024

;

30

(

4

):

415.e1

-

415.e16

.

71.

Morishita

S

,

Kaida

K

,

Tanaka

T

, et al.

Prevalence of sarcopenia and relevance of body composition, physiological function, fatigue, and health-related quality of life in patients before allogeneic hematopoietic stem cell transplantation

.

Support Care Cancer

.

2012

;

20

(

12

):

3161

-

3168

.

72.

Ando

T

,

Fujisawa

S

,

Teshigawara

H

, et al.

Computed tomography-defined sarcopenia: prognostic predictor of nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study

.

Int J Hematol

.

2020

;

112

(

1

):

46

-

56

.

73.

Miyazaki

T

,

Tachibana

T

,

Suzuki

T

, et al.

Pretransplantation inflammatory and nutritional status in elderly allogeneic hematopoietic stem cell transplantation: prognostic value of C-reactive protein-to-albumin ratio

.

Transplant Cell Ther

.

2024

;

30

(

4

):

400.e1

-

400.e9

.

74.

Artz

A

,

Logan

BR

,

Saber

W

, et al.

The Composite Health Risk Assessment Model (CHARM) to predict 1-year non-relapse mortality (NRM) among older recipients of allogeneic transplantation: a prospective BMT-CTN study 1704 [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

109

.

75.

Abid

MB

,

Estrada-Merly

N

,

Zhang

MJ

, et al.

Impact of donor age on allogeneic hematopoietic cell transplantation outcomes in older adults with acute myeloid leukemia

.

Transplant Cell Ther

.

2023

;

29

(

9

):

578.e1

-

578.e9

.

76.

Kollman

C

,

Spellman

SR

,

Zhang

MJ

, et al.

The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy

.

Blood

.

2016

;

127

(

2

):

260

-

267

.

77.

Petersdorf

EW

,

Bengtsson

M

,

De Santis

D

, et al.

Role of HLA-DP expression in graft-versus-host disease after unrelated donor transplantation

.

J Clin Oncol

.

2020

;

38

(

24

):

2712

-

2718

.

78.

Mayor

NP

,

Wang

T

,

Lee

SJ

, et al.

Impact of previously unrecognized HLA mismatches using ultrahigh resolution typing in unrelated donor hematopoietic cell transplantation

.

J Clin Oncol

.

2021

;

39

(

21

):

2397

-

2409

.

79.

Crivello

P

,

Arrieta-Bolaños

E

,

He

M

, et al.

Impact of the HLA immunopeptidome on survival of leukemia patients after unrelated donor transplantation

.

J Clin Oncol

.

2023

;

41

(

13

):

2416

-

2427

.

80.

Kasamon

YL

,

Bolaños-Meade

J

,

Prince

GT

, et al.

Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults

.

J Clin Oncol

.

2015

;

33

(

28

):

3152

-

3161

.

81.

Slade

M

,

DiPersio

JF

,

Westervelt

P

,

Vij

R

,

Schroeder

MA

,

Romee

R

.

Haploidentical hematopoietic cell transplant with post-transplant cyclophosphamide and peripheral blood stem cell grafts in older adults with acute myeloid leukemia or myelodysplastic syndrome

.

Biol Blood Marrow Transplant

.

2017

;

23

(

10

):

1736

-

1743

.

82.

Ciurea

SO

,

Shah

MV

,

Saliba

RM

, et al.

Haploidentical transplantation for older patients with acute myeloid leukemia and myelodysplastic syndrome

.

Biol Blood Marrow Transplant

.

2018

;

24

(

6

):

1232

-

1236

.

83.

Bashey

ZA

,

Zhang

X

,

Brown

S

, et al.

Comparison of outcomes following transplantation with T-replete HLA-haploidentical donors using post-transplant cyclophosphamide to matched related and unrelated donors for patients with AML and MDS aged 60 years or older

.

Bone Marrow Transplant

.

2018

;

53

(

6

):

756

-

763

.

84.

Devillier

R

,

Legrand

F

,

Rey

J

, et al.

HLA-matched sibling versus unrelated versus haploidentical related donor allogeneic hematopoietic stem cell transplantation for patients aged over 60 years with acute myeloid leukemia: a single-center donor comparison

.

Biol Blood Marrow Transplant

.

2018

;

24

(

7

):

1449

-

1454

.

85.

Imus

PH

,

Tsai

HL

,

Luznik

L

, et al.

Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70

.

Blood Adv

.

2019

;

3

(

17

):

2608

-

2616

.

86.

Sandmaier

BM

,

Kornblit

B

,

Storer

BE

, et al.

Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial

.

Lancet Haematol

.

2019

;

6

(

8

):

e409

-

e418

.

87.

Shah

MV

,

Saliba

RM

,

Rondon

G

, et al.

Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation

.

Bone Marrow Transplant

.

2019

;

54

(

4

):

601

-

606

.

88.

Shaw

BE

,

Jimenez-Jimenez

AM

,

Burns

LJ

, et al.

National Marrow Donor Program-sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide

.

J Clin Oncol

.

2021

;

39

(

18

):

1971

-

1982

.

89.

Wegener

A

,

Andersen

NS

,

Friis

LS

, et al.

Triple-drug graft-versus-host disease prophylaxis after HLA-matched unrelated donor nonmyeloablative allogenic hematopoietic stem cell transplantation

.

Transplant Cell Ther

.

2023

;

29

(

9

):

575.e1

-

575.e6

.

90.

Raghunandan

S

,

Qayed

M

,

Watkins

BK

, et al.

Abatacept for graft versus host disease prophylaxis in patients 60 years and older receiving mismatched unrelated donor transplantation for hematologic malignancies

.

Bone Marrow Transplant

.

2023

;

58

(

11

):

1264

-

1266

.

91.

Morsink

LM

,

Hazenberg

CLE

,

Choi

G

, et al.

Improved outcome of allogeneic transplantation in older patients treated for myeloid malignancies using post-transplantation cyclophosphamide and reduced duration of immune suppression

.

Transplant Cell Ther

.

2024

;

30

(

8

):

794

-

807

.

92.

Bolaños-Meade

J

,

Hamadani

M

,

Wu

J

, et al.

Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis

.

N Engl J Med

.

2023

;

388

(

25

):

2338

-

2348

.

93.

Sanz

J

,

Labopin

M

,

Choi

G

, et al.

Younger unrelated donors may be preferable over HLA match in the PTCy era: a study from the ALWP of the EBMT

.

Blood

.

2024

;

143

(

24

):

2534

-

2543

.

94.

McCurdy

SR

,

Hyder

MA

,

Sabina

R

, et al.

Interim results of a phase I/II trial of intermediate-dose post-transplantation cyclophosphamide after reduced intensity conditioned HLA-mismatched bone marrow transplantation for older or unfit patients [review]

.

Transplant Cell Ther

.

2024

;

30

(

2

):

S2

-

S3

.

95.

Rafii

H

,

Ruggeri

A

,

Volt

F

, et al.

Changing trends of unrelated umbilical cord blood transplantation for hematologic diseases in patients older than fifty years: a Eurocord-Center for International Blood and Marrow Transplant Research survey

.

Biol Blood Marrow Transplant

.

2016

;

22

(

9

):

1717

-

1720

.

96.

Sandhu

KS

,

Brunstein

C

,

DeFor

T

, et al.

Umbilical cord blood transplantation outcomes in acute myelogenous leukemia/myelodysplastic syndrome patients aged >/=70 years

.

Biol Blood Marrow Transplant

.

2016

;

22

(

2

):

390

-

393

.

97.

Harbi

S

,

Brac de la Perriere

L

,

Bouchacourt

B

, et al.

Peripheral blood haploidentical hematopoietic cell transplantation for patients aged 70 years and over with acute myeloid leukemia or high-risk myelodysplastic syndrome

.

Bone Marrow Transplant

.

2024

;

59

(

1

):

101

-

106

.

98.

Lancet

JE

,

Uy

GL

,

Cortes

JE

, et al.

CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia

.

J Clin Oncol

.

2018

;

36

(

26

):

2684

-

2692

.

99.

Uy

GL

,

Newell

LF

,

Lin

TL

, et al.

Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and/or secondary AML

.

Blood Adv

.

2022

;

6

(

17

):

4989

-

4993

.

100.

Lübbert

M

,

Wijermans

PW

,

Kicinski

M

, et al.

10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial

.

Lancet Haematol

.

2023

;

10

(

11

):

e879

-

e889

.

101.

Hilberink

J

,

Hazenberg

C

,

van den Berg

E

, et al.

Not type of induction therapy but consolidation with allogeneic hematopoietic cell transplantation determines outcome in older AML patients: a single center experience of 355 consecutive patients

.

Leuk Res

.

2019

;

80

:

33

-

39

.

102.

DiNardo

CD

,

Jonas

BA

,

Pullarkat

V

, et al.

Azacitidine and venetoclax in previously untreated acute myeloid leukemia

.

N Engl J Med

.

2020

;

383

(

7

):

617

-

629

.

103.

Pratz

KW

,

Jonas

BA

,

Pullarkat

V

, et al.

Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia

.

Am J Hematol

.

2024

;

99

(

4

):

615

-

624

.

104.

DiNardo

CD

,

Schuh

AC

,

Stein

EM

, et al.

Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial

.

Lancet Oncol

.

2021

;

22

(

11

):

1597

-

1608

.

105.

Montesinos

P

,

Recher

C

,

Vives

S

, et al.

Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia

.

N Engl J Med

.

2022

;

386

(

16

):

1519

-

1531

.

106.

Winters

AC

,

Bosma

G

,

Abbott

D

, et al.

Outcomes are similar after allogeneic hematopoietic stem cell transplant for newly diagnosed acute myeloid leukemia patients who received venetoclax + azacitidine versus intensive chemotherapy

.

Transplant Cell Ther

.

2022

;

28

(

10

):

694.e1

-

694.e9

.

107.

Kadia

TM

,

Reville

PK

,

Wang

X

, et al.

Phase II study of venetoclax added to cladribine plus low-dose cytarabine alternating with 5-azacitidine in older patients with newly diagnosed acute myeloid leukemia

.

J Clin Oncol

.

2022

;

40

(

33

):

3848

-

3857

.

108.

Short

NJ

,

Daver

N

,

Dinardo

CD

, et al.

Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML

.

J Clin Oncol

.

2024

;

42

(

13

):

1499

-

1508

.

109.

Hilberink

JR

,

Morsink

LM

,

van der Velden

WJFM

, et al.

Pretransplantation MRD in older patients with AML after treatment with decitabine or conventional chemotherapy

.

Transplant Cell Ther

.

2021

;

27

(

3

):

246

-

252

.

110.

Fasslrinner

F

,

Schetelig

J

,

Burchert

A

, et al.

Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial

.

Lancet Haematol

.

2018

;

5

(

4

):

e161

-

e169

.

111.

Scott

BL

,

Pasquini

MC

,

Fei

M

, et al.

Myeloablative versus reduced-intensity conditioning for hematopoietic cell transplantation in acute myelogenous leukemia and myelodysplastic syndromes-long-term follow-up of the BMT CTN 0901 clinical trial

.

Transplant Cell Ther

.

2021

;

27

(

6

):

483.e1

-

483.e6

.

112.

Blaise

D

,

Tabrizi

R

,

Boher

JM

, et al.

Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigen-matched, related allogeneic peripheral blood stem cell transplantation: prospective clinical and socioeconomic evaluation

.

Cancer

.

2013

;

119

(

3

):

602

-

611

.

113.

Beelen

DW

,

Stelljes

M

,

Reményi

P

, et al.

Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: final analysis of a prospective randomized trial

.

Am J Hematol

.

2022

;

97

(

8

):

1023

-

1034

.

114.

Craddock

C

,

Jackson

A

,

Loke

J

, et al.

Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia

.

J Clin Oncol

.

2021

;

39

(

7

):

768

-

778

.

115.

Gyurkocza

B

,

Nath

R

,

Seropian

S

, et al.

Randomized phase III SIERRA trial of 131I-apamistamab before allogeneic hematopoietic cell transplantation vs conventional care for relapsed/refractory acute myeloid leukemia

.

J Clin Oncol

.

Forthcoming 2024

.

116.

Craddock

C

,

Nagra

S

,

Peniket

A

, et al.

Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia

.

Haematologica

.

2010

;

95

(

6

):

989

-

995

.

117.

Baron

F

,

Labopin

M

,

Niederwieser

D

, et al.

Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation

.

Leukemia

.

2012

;

26

(

12

):

2462

-

2468

.

118.

Loke

J

,

McCarthy

N

,

Jackson

A

, et al.

Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML/MDS

.

Blood Adv

.

2023

;

7

(

14

):

3666

-

3676

.

119.

de Lima

M

,

Giralt

S

,

Thall

PF

, et al.

Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study

.

Cancer

.

2010

;

116

(

23

):

5420

-

5431

.

120.

Platzbecker

U

,

Wermke

M

,

Radke

J

, et al.

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial

.

Leukemia

.

2012

;

26

(

3

):

381

-

389

.

121.

Platzbecker

U

,

Middeke

JM

,

Sockel

K

, et al.

Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial

.

Lancet Oncol

.

2018

;

19

(

12

):

1668

-

1679

.

122.

Bewersdorf

JP

,

Allen

C

,

Mirza

AS

, et al.

Hypomethylating agents and FLT3 inhibitors as maintenance treatment for acute myeloid leukemia and myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation-a systematic review and meta-analysis

.

Transplant Cell Ther

.

2021

;

27

(

12

):

997.e1

-

997.e11

.

123.

de Lima

M

,

Oran

B

,

Champlin

RE

, et al.

CC-486 maintenance after stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndromes

.

Biol Blood Marrow Transplant

.

2018

;

24

(

10

):

2017

-

2024

.

124.

Wei

AH

,

Döhner

H

,

Pocock

C

, et al.

Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission

.

N Engl J Med

.

2020

;

383

(

26

):

2526

-

2537

.

125.

Stone

RM

,

Mandrekar

SJ

,

Sanford

BL

, et al.

Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation

.

N Engl J Med

.

2017

;

377

(

5

):

454

-

464

.

126.

Perl

AE

,

Martinelli

G

,

Cortes

JE

, et al.

Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML

.

N Engl J Med

.

2019

;

381

(

18

):

1728

-

1740

.

127.

Erba

HP

,

Montesinos

P

,

Kim

HJ

, et al.

Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial

.

Lancet

.

2023

;

401

(

10388

):

1571

-

1583

.

128.

Burchert

A

,

Bug

G

,

Fritz

LV

, et al.

Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)

.

J Clin Oncol

.

2020

;

38

(

26

):

2993

-

3002

.

129.

Maziarz

RT

,

Levis

M

,

Patnaik

MM

, et al.

Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia

.

Bone Marrow Transplant

.

2021

;

56

(

5

):

1180

-

1189

.

130.

Xuan

L

,

Wang

Y

,

Yang

K

, et al.

Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial

.

Lancet Haematol

.

2023

;

10

(

8

):

e600

-

e611

.

131.

Levis

MJ

,

Hamadani

M

,

Logan

B

, et al.

Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3

.

J Clin Oncol

.

2024

;

42

(

15

):

1766

-

1775

.

132.

Short

NJ

,

Nguyen

D

,

Ravandi

F

.

Treatment of older adults with FLT3-mutated AML: emerging paradigms and the role of frontline FLT3 inhibitors

.

Blood Cancer J

.

2023

;

13

(

1

):

142

.

133.

Daver

NG

,

Craddock

C

.

Moving toward total therapy in AML: personalized treatments improve post-transplant outcome

.

J Clin Oncol

.

2024

;

42

(

15

):

1731

-

1733

.

134.

de Botton

S

,

Fenaux

P

,

Yee

K

, et al.

Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML

.

Blood Adv

.

2023

;

7

(

13

):

3117

-

3127

.

135.

Issa

GC

,

Aldoss

I

,

DiPersio

J

, et al.

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia

.

Nature

.

2023

;

615

(

7954

):

920

-

924

.

136.

Fathi

AT

,

Kim

HT

,

Soiffer

RJ

, et al.

Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies

.

Blood Adv

.

2022

;

6

(

22

):

5857

-

5865

.

137.

Fathi

AT

,

Kim

HT

,

Soiffer

RJ

, et al.

Multicenter phase I trial of ivosidenib as maintenance treatment following allogeneic hematopoietic cell transplantation for IDH1-mutated acute myeloid leukemia

.

Clin Cancer Res

.

2023

;

29

(

11

):

2034

-

2042

.

138.

Salhotra

A

,

Bejanyan

N

,

Yang

D

, et al.

Multicenter pilot clinical trial of enasidenib as maintenance therapy after allogeneic hematopoietic cell transplantation (alloHCT) in patients with acute myeloid leukemia (AML) varrying IDH2 mutations [abstract]

.

Transplant Cell Ther

.

2024

;

30

(

suppl

):

S8

.

139.

Lee

HC

,

Saliba

RM

,

Rondon

G

, et al.

Mixed T lymphocyte chimerism after allogeneic hematopoietic transplantation is predictive for relapse of acute myeloid leukemia and myelodysplastic syndromes

.

Biol Blood Marrow Transplant

.

2015

;

21

(

11

):

1948

-

1954

.

140.

Krishnamurthy

P

,

Potter

VT

,

Barber

LD

, et al.

Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes

.

Biol Blood Marrow Transplant

.

2013

;

19

(

4

):

562

-

568

.

141.

Schmid

C

,

Labopin

M

,

Schaap

N

, et al.

Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the Acute Leukaemia Working Party of EBMT

.

Br J Haematol

.

2019

;

184

(

5

):

782

-

787

.

142.

Tsirigotis

P

,

Gkirkas

K

,

Kitsiou

V

, et al.

Repetitively administered low-dose donor lymphocyte infusion for prevention of relapse after allogeneic stem cell transplantation in patients with high-risk acute leukemia

.

Cancers

.

2021

;

13

(

11

):

2699

.

143.

Schmid

C

,

Labopin

M

,

Schaap

N

, et al.

Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia

.

Bone Marrow Transplant

.

2022

;

57

(

2

):

215

-

223

.

144.

Sauerer

T

,

Velázquez

GF

,

Schmid

C

.

Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: immune escape mechanisms and current implications for therapy

.

Mol Cancer

.

2023

;

22

(

1

):

180

.

145.

Orvain

C

,

Ali

N

,

Othus

M

, et al.

Relative prognostic value of flow cytometric measurable residual disease before allogeneic hematopoietic cell transplantation for adults with MDS/AML or AML

.

Am J Hematol

.

2024

;

99

(

5

):

862

-

870

.